Monitor stockholder vote outcome on July 31, 2026 — failure to obtain disinterested stockholder approval would terminate the deal. Post-vote, track HSR clearance and Indian FEMA approval for closing timeline. The 28.9M share issuance (9.1% dilution relative to outstanding 319.3M shares) weighs on near-term price, but the cash consideration and milestone/royalty structure provide upside optionality on Kashiv biosimilar pipeline.
Price Chart
Executive Summary
Amneal is soliciting stockholder approval for its acquisition of Kashiv BioSciences, a vertically integrated biosimilars company, for $375M in cash plus 28,942,108 shares of Amneal Class A common stock, with up to $350M in contingent regulatory milestones and 12-year royalty payments on gross profit hurdles. The transaction is structured to comply with DGCL Section 144 safe harbor protections and Nasdaq Listing Rule 5635(a)(2) due to conflicts of interest involving Amneal's co-CEOs and directors who are also Kashiv equity holders. The Independent Committee and Amneal Board unanimously recommend voting FOR both proposals, with the special meeting scheduled for July 31, 2026.
Key Financial Metrics
Key Facts
- Amneal to acquire 100% of Kashiv BioSciences for $375M cash + 28,942,108 shares of Amneal Class A common stock
- Up to $350M in contingent regulatory milestone payments for up to 6 designated Kashiv product candidates
- 12-year contingent royalty payments equal to 25% of annual aggregate gross profits exceeding specified hurdle amounts
- Transaction conditioned on approval by Amneal disinterested stockholders (majority of votes cast) and Amneal stockholders (majority of votes cast)
- Special meeting to be held online July 31, 2026 at 9:00 AM ET
- Goldman Sachs provided fairness opinion — total fee $15M, with $12.5M contingent on closing
- HSR Act filings made May 19, 2026; Indian regulatory approval application submitted June 15, 2026 under FEMA
- Expected closing in second half of 2026
- Chirag Patel, Chintu Patel, Gautam Patel, and other Amneal directors/executives have direct or indirect equity interests in Kashiv — transaction designed for Section 144 safe harbor
- Outside date for closing is November 17, 2026, with automatic extension to January 12, 2027 for pending regulatory approvals
Financial Impact
Total upfront cash consideration of $375,000,000 plus issuance of 28,942,108 shares of Amneal Class A common stock. Contingent milestone payments up to $350,000,000. Royalty stream of 25% of gross profits above hurdles over 12 years.
Risk Factors
- Stockholder vote failure — disinterested stockholder rejection kills deal
- Regulatory delay or denial — HSR or Indian FEMA approval risks
- Dilution of 9.1% from share issuance
- Conflicts of interest create litigation risk despite Section 144 safe harbor structure
- Integration risk for biosimilars business
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001140361-26-026611 |
| Document: ny20075452x2_defm14a.htm | 0001140361-26-026611 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K/A | $20.38 | awaiting T+60 | — | $21.02 (+3.14%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.02 (+4.27%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.02 (−15.81%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.02 (+22.92%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.02 (+13.62%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.02 (+17.76%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers